angiotensin ii, des-phe(8)- has been researched along with Carcinoma, Renal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cudnoch-Jedrzejewska, A; Girstun, A; Koperski, L; Sobczuk, P; Trzcinska-Danielewicz, J | 1 |
| Amin, S; Bakouny, Z; Bhasin, M; Bhatt, RS; Catalano, P; Chen, CH; Choueiri, TK; Joslin, PN; Khanna, P; McKay, R; Moore, A; Naughton, M; O'Callaghan, C; Saxena, R; Signoretti, S; Soh, HJ; Walther, T | 1 |
2 other study(ies) available for angiotensin ii, des-phe(8)- and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Angiotensin-(1-7) can promote cell migration and tumor growth of clear cell renal cell carcinoma.
Topics: Angiotensin I; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Humans; Kidney Neoplasms; Mice; Mice, Nude; Peptide Fragments; Proto-Oncogene Mas | 2022 |
ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Peptide Fragments; Peptidyl-Dipeptidase A; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2021 |